Anti-HIV-1 gene therapy

Cullen, 1991, Regulation of HIV-1 replication, Annu Rev Microbiol, 45, 219, 10.1146/annurev.mi.45.100191.001251 Levy, 1988, Mysteries of HIV: challenges for therapy and prevention, Nature, 333, 519, 10.1038/333519a0 Haseltine, 1991, Molecular biology of HIV-1, FASEB J, 5, 2349, 10.1096/fasebj.5.10.1829694 Yashwantrai, 1991, The Biochemistry of AIDS, Annu Rev Biochem, 60, 577, 10.1146/annurev.bi.60.070191.003045 Cullen, 1991, Regulation of HIV-1 gene expression, FASEB J, 10, 2361, 10.1096/fasebj.5.10.1712325 Stevenson, 1992, HIV-1 replication and potential targets for intervention, AIDS Res Hum Retro, 8, 107, 10.1089/aid.1992.8.107 Sattentau, 1988, The CD4 antigen: physiological ligand and HIV receptor, Cell, 52, 631, 10.1016/0092-8674(88)90397-2 Pomerantz, 1995, Genetic therapies for HIV infections: promise for the future, AIDS, 9, 985, 10.1097/00002030-199509000-00002 Joshi S, Joshi RL: Molecular biology of HIV-1. Transfus Sci (in press). Cullen, 1994, RNA-sequence-mediated gene regulation in HIV-1, Infect Agents Dis, 3, 68 Poeschla, 1994, Molecular biology of HIV: challenges for the second decade, AIDS Res Hum Retro, 10, 111, 10.1089/aid.1994.10.111 Subbramanian, 1994, Molecular biology of the HIV accessory proteins, J Virol, 68, 6831, 10.1128/JVI.68.11.6831-6835.1994 Trono, 1995, HIV accessory proteins: leading roles for the supporting cast, Cell, 82, 189, 10.1016/0092-8674(95)90306-2 Gaynor, 1992, Cellular transcription factors involved in the regulation of HIV-1 gene expression, AIDS, 6, 347, 10.1097/00002030-199204000-00001 Ahmad, 1988, Nef protein of HIV-1 is a transcriptional repressor of HIV-1 LTR, Science, 241, 1481, 10.1126/science.3262235 Cann, 1989, Molecular biology of HIV: new insights into the virus life-cycle, AIDS 3, S19, 10.1097/00002030-198901001-00004 Panganiban, 1988, Ordered interstrand and intrastrand DNA transfer during reverse transcription, Science, 241, 1064, 10.1126/science.2457948 Green, 1989, Mutational analysis of HIV-1 Tat minimal domain peptides: identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression, Cell, 58, 215, 10.1016/0092-8674(89)90417-0 Pearson, 1990, A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat, 87, 5079 Kjems, 1991, Structural analysis of the interaction between the HIV Rev protein and the Rev response element, 88, 683 Malim, 1989, Functional dissection of the HIV-1 Rev trans-activator-derivation of a trans-dominant repressor of Rev function, Cell, 58, 205, 10.1016/0092-8674(89)90416-9 Modesti, 1991, Trans-dominant Tat mutants with alterations in the basic domain inhibit HIV-1 gene expression, New Biol, 3, 759 Mermer, 1990, Identification of Transdominant HIV-1 rev protein mutants by direct transfer of bacterially produced proteins into human cells, Nucl Acids Res, 18, 2037, 10.1093/nar/18.8.2037 Venkatesh, 1990, Mutants in a conserved region near the carboxy-terminus of HIV-1 Rev identify functionally important residues and exhibit a dominant negative phenotype, Virology, 178, 327, 10.1016/0042-6822(90)90414-M Hope, 1992, Trans-dominant inhibition of HIV-1 Rev occurs through formation of inactive protein complexes, J Virol, 66, 1849, 10.1128/JVI.66.4.1849-1855.1992 Olsen, 1990, Interaction of the HIV1 Rev protein with a structured region in env mRNA is dependent on multimer formation mediated through a basic stretch of amino acids, Gene Dev, 4, 1357, 10.1101/gad.4.8.1357 Rabson, 1985, Molecular organization of the AIDS retrovirus, Cell, 40, 477, 10.1016/0092-8674(85)90189-8 Trono, 1989, HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus, Cell, 59, 113, 10.1016/0092-8674(89)90874-X Freed, 1992, A mutation in the HIV-1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity, 89, 70 Eglitis, 1988, Retroviral vectors for introduction of genes into mammalian cells, Biotechniques, 6, 608 Miller, 1989, Improved retroviral vectors for gene transfer and expression, Biotechniques, 7, 980 Miller, 1990, Retrovirus packaging cells, Hum Gene Ther, 1, 5, 10.1089/hum.1990.1.1-5 Miller, 1990, Progress toward human gene therapy, Blood, 76, 271, 10.1182/blood.V76.2.271.271 van der Krol, 1988, Modulation of eukaryotic gene expression by complementary RNA or DNA sequences, Biotechniques, 6, 958 Rhodes, 1990, Inhibition of HIV replication in cell culture by endogenously synthesized antisense RNA, J Gen Virol, 71, 1965, 10.1099/0022-1317-71-9-1965 Sczakiel, 1990, Specific inhibition of HIV-1 replication by RNA transcribed in sense and antisense orientation from the 5′-leader/gag region, Biochem Biophys Res Commun, 169, 643, 10.1016/0006-291X(90)90379-2 Sczakiel, 1991, Inhibition of HIV-1 replication in human T cells stably expressing antisense RNA, J Virol, 65, 468, 10.1128/JVI.65.1.468-472.1991 Joshi, 1991, Inhibition of HIV-1 multiplication by antisense and sense RNA expression, J Virol, 65, 5524, 10.1128/JVI.65.10.5524-5530.1991 Cohli, 1994, Inhibition of HIV-1 multiplication in a human CD4+ lymphocytic cell line expressing antisense and sense RNA molecules containing HIV-1 packaging signal and Rev response element(s), Antisense Res Dev, 4, 19, 10.1089/ard.1994.4.19 Zimmermann, 1992, Expression of chimeric neo-Rev response element sequences interferes with Rev-dependent HIV-1 Gag expression, Hum Gene Ther, 3, 155, 10.1089/hum.1992.3.2-155 Lisziewicz, 1991, Tat-regulated production of multimerized TAR RNA inhibits HIV-1 gene expression, New Biol, 3, 82 Lisziewicz, 1993, Inhibition of HIV-1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS, 90, 8000 Sullenger, 1990, Overexpression of TAR sequences renders cells resistant to HIV replication, Cell, 63, 601, 10.1016/0092-8674(90)90455-N Sullenger, 1991, Analysis of transacting response decoy RNA-mediated inhibition of HIV-1 transactivation, J Virol, 65, 6811, 10.1128/JVI.65.12.6811-6816.1991 Lee, 1992, Overexpression of RREderived sequences inhibits HIV-1 replication in CEM cells, New Biol, 4, 66 Bevec, 1994, Constitutive expression of chimeric neo-Rev response element transcripts suppresses HIV-1 replication in human CD4+ T lymphocytes, Hum Gene Ther, 5, 193, 10.1089/hum.1994.5.2-193 Weerasinghe, 1991, Resistance to HIV-1 infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme, J Virol, 65, 5531, 10.1128/JVI.65.10.5531-5534.1991 Heidenreich, 1992, Hammerhead ribozyme-mediated cleavage of the long terminal repeat RNA of HIV-1, J Biol Chem, 267, 1904, 10.1016/S0021-9258(18)46032-2 Dropulic, 1992, Functional characterization of a U5 ribozyme: intracellular suppression of HIV-1 expression, J Virol, 66, 1432, 10.1128/JVI.66.3.1432-1441.1992 Sarver, 1990, Ribozymes as potential anti-HIV-1 therapeutic agents, Science, 247, 1222, 10.1126/science.2107573 Ramezani A, et al.: Inhibition of HIV-1 multiplication in a human CD4+ lymphocytic cell line expressing hammerhead ribozymes directed against HIV-1 mRNAs containing Gag, Pro, RT, Tat, and Env coding regions. (Submitted). Lorentzen, 1991, In vitro cleavage of HIV-1 vif RNA by a synthetic ribozyme, Virus Genes, 5, 17, 10.1007/BF00571727 Zhou, 1994, Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes, Gene, 1994, 33 Ojwang, 1993, Inhibition of HIV-1 expression by a hairpin ribozyme, 89, 1082 Yu, 1993, A hairpin ribozyme inhibits expression of diverse strains of HIV-1, 90, 6340 Yamada, 1994, Intracellular immunization of human T-cells with a hairpin ribozyme against HIV-1, Gene Ther, 1, 38 Kubota, 1992, Inhibition of HIV-1 Rev function by a Rev mutant which interferes with nuclear/nucleolar localization of Rev, J Virol, 66, 2510, 10.1128/JVI.66.4.2510-2513.1992 Smythe, 1994, A rev-inducible mutant gag gene stably transformed into T lymphocytes: an approach to gene therapy against HIV-1 infection, 91, 3657 Bahner, 1993, Comparison of transdominant inhibitory mutant HIV-1 genes expressed by retroviral vectors in human T lymphocytes, J Virol, 67, 3199, 10.1128/JVI.67.6.3199-3207.1993 Liem, 1993, The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance, Hum Gene Ther, 4, 625, 10.1089/hum.1993.4.5-625 Lisziewicz, 1994, A Rev-inducible mutant gag gene stably transferred into T lymphocytes: an approach to therapy against HIV-1 infection, 91, 3657 Harrison, 1991, Activation of a diphtheria toxin A gene by expression of HIV-1 Tat and Rev proteins in transfected cells, Hum Gene Ther, 2, 53, 10.1089/hum.1991.2.1-53 Harrison, 1992, Inhibition of HIV production in cells containing an integrated, HIV-regulated diphtheria toxin A chain gene, AIDS Res Hum Retro, 8, 39, 10.1089/aid.1992.8.39 Curiel, 1993, Long-term inhibition of clinical and laboratory HIV strains in human T-cell lines containing an HIV-regulated diptheria toxin A chain gene, Hum Gene Ther, 5, 193 Caruso, 1992, Selective killing of CD4+ cells harboring a HIVinducible suicide gene prevents viral spread in an infected cell population, 89, 182 Morgan, 1990, Retroviral vectors expressing soluble CD4: a potential gene therapy for AIDS, AIDS Res Hum Retro, 6, 183, 10.1089/aid.1990.6.183 Mhashilkar, 1994, Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies, EMBO J, 14, 1542, 10.1002/j.1460-2075.1995.tb07140.x Duan, 1994, Potent inhibition of HIV type 1 replication by an intracellular anti-Rev single-chain antibody, 91, 5075 Marasco, 1993, Design, intrcellular expression, and activity of a HIV-1 gpl20 single-chain antibody, 90, 7889 Nabel G, et al.: Clinical Protocol (Rev M10). Information available upon request from the NIH Recombinant Advisory Committee (RAC). Wong-Staal F, et al.: Clinical Protocol (Ribozyme). Information available upon request from the NIH Recombinant Advisory Committee (RAC).